Loading company…
Repairon develops regenerative heart therapies using induced pluripotent stem cells, including engineered heart tissue patches.
Founded in 2014, Repairon develops induced pluripotent stem cell therapies for heart failure. Its Engineered Human Myocardium patches are designed to help restore function in failing hearts. Based in Göttingen, Germany, the company raised Series A funding in October 2025, led by Bioventure Management GmbH with participation from Sartorius AG, to advance its therapies and initiate a European Phase 3 trial.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in